Literature DB >> 18957806

Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects.

Yoshinori Miyazaki1, Hiroshi Akasaka, Hirofumi Ohnishi, Shigeyuki Saitoh, Ralph A DeFronzo, Kazuaki Shimamoto.   

Abstract

We examined insulin action/secretion and cardiovascular disease risk factors in Japanese subjects with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) who were not taking any medications known to affect glucose tolerance, blood pressure (BP) or plasma lipids (PLs). A total of 1,399 subjects received measurements of anthropometry, BP, PLs, and plasma glucose/insulin concentrations during 75 g-oral glucose tolerance test (OGTT). According to 2003 American Diabetes Association criteria, subjects were classified as having normal fasting glucose (NFG)/normal glucose tolerance (NGT) (n = 1,173), IFG (n = 128), IGT (n = 55), and IFG/IGT (n = 43). Insulin action was calculated using the HOMA-R (index of hepatic insulin resistance) and Matsuda index (reflects whole body insulin sensitivity). The ratio of the incremental area under the curve of insulin to that of glucose during OGTT (delta AUC(PI)/delta AUC(PG)) was used as an index of beta-cell function. HOMA-R was higher in IFG (2.3 +/- 0.1) and IFG/IGT (2.5 +/- 0.2) than in NFG/NGT (1.8 +/- 0.03). The Matsuda index was lower in IFG (6.5 +/- 0.3), IGT (5.4 +/- 0.4) and IFG/IGT (5.1 +/- 0.5) than in NFG/NGT (9.6 +/- 0.2). Delta AUC(PI)/delta AUC(PG) was lower in IGT (0.6 +/- 0.05) and IFG/IGT (0.5 +/- 0.05) than in IFG (1.4 +/- 0.12) or NFG/NGT (1.2 +/- 0.03). Mean BP was higher in IGT (100 +/- 1.7 mmHg) than in NFG/NGT (91 +/- 0.3) or IFG (95 +/- 1.1). The plasma triglyceride level was higher in IGT (155 +/- 14 mg/dL) and IGT/IFG (173 +/- 12) than in IFG (132 +/- 7) or NFG/NGT (122 +/- 2). In conclusion, 1) whole body insulin sensitivity is decreased in IFG and IGT, with a greater reduction in IGT, 2) hepatic insulin resistance and preserved beta-cell function are characteristics of IFG, and 3) higher BP and triglyceride levels are observed in IGT. IGT is more closely associated with risk factors for cardiovascular disease than is IFG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18957806     DOI: 10.1291/hypres.31.1357

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  5 in total

1.  Effect of adiposity on insulin action after acute and chronic resistance exercise in non-diabetic women.

Authors:  Steven K Malin; Kristi R Hinnerichs; Brandon G Echtenkamp; Tammy K Evetovich; Barbara J Engebretsen
Journal:  Eur J Appl Physiol       Date:  2013-09-27       Impact factor: 3.078

2.  Insulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance.

Authors:  Sae Aoyama-Sasabe; Mitsuo Fukushima; Xin Xin; Ataru Taniguchi; Yoshikatsu Nakai; Rie Mitsui; Yoshitaka Takahashi; Hideaki Tsuji; Daisuke Yabe; Koichiro Yasuda; Takeshi Kurose; Nobuya Inagaki; Yutaka Seino
Journal:  J Diabetes Res       Date:  2015-12-15       Impact factor: 4.011

Review 3.  Ectopic Fat Accumulation in Distinct Insulin Resistant Phenotypes; Targets for Personalized Nutritional Interventions.

Authors:  Inez Trouwborst; Suzanne M Bowser; Gijs H Goossens; Ellen E Blaak
Journal:  Front Nutr       Date:  2018-09-04

4.  Effects of the association of different volumes of strength training with photobiomodulation therapy on insulin resistance: A protocol for a randomized, triple-blind, placebo-controlled trial.

Authors:  Pedro Paulo Ribeiro Ferreira; Luís Filipe Rocha Silva; Marco Fabrício Dias-Peixoto; Ricardo Cardoso Cassilhas; Fernando Gripp; Fabiano Trigueiro Amorim; Zachary A Mang; Elizabethe Adriana Esteves; Valmor A Tricoli; Cleber Ferraresi; Flávio de Castro Magalhães
Journal:  Contemp Clin Trials Commun       Date:  2022-08-17

5.  Evidence of reduced β-cell function in Asian Indians with mild dysglycemia.

Authors:  Lisa R Staimez; Mary Beth Weber; Harish Ranjani; Mohammed K Ali; Justin B Echouffo-Tcheugui; Lawrence S Phillips; Viswanathan Mohan; K M Venkat Narayan
Journal:  Diabetes Care       Date:  2013-04-17       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.